Search Result

Pathways Recommended:	Anti-infection

Results for "

SARSCoV-2 infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (78) AAK1 (2) Akt (2) Angiotensin-converting Enzyme (ACE) (5) Antibiotic (11) Apoptosis (3) Autophagy (20) Bacterial (3) Cathepsin (1) CDK (1) DNA/RNA Synthesis (7) Drug Metabolite (3) EGFR (1) Endogenous Metabolite (2) ERK (1) FXR (4) G protein-coupled Bile Acid Receptor 1 (2) HBV (1) HCV (2) HDAC (1) Histamine Receptor (1) Histone Methyltransferase (1) HIV (13) Influenza Virus (1) Isotope-Labeled Compounds (6) MDM-2/p53 (1) Microtubule/Tubulin (1) MMP (1) PAI-1 (1) Parasite (17) PKC (1) Ser/Thr Protease (3) Toll-like Receptor (TLR) (18) VEGFR (2) Virus Protease (7)
By Research Areas:	Cancer (24) Cardiovascular Disease (2) Infection (75) Inflammation/Immunology (9) Metabolic Disease (10)

By Targets:

SARS-CoV (78)

AAK1 (2)

Akt (2)

Angiotensin-converting Enzyme (ACE) (5)

Antibiotic (11)

Apoptosis (3)

Autophagy (20)

Bacterial (3)

Cathepsin (1)

CDK (1)

DNA/RNA Synthesis (7)

Drug Metabolite (3)

EGFR (1)

Endogenous Metabolite (2)

ERK (1)

FXR (4)

G protein-coupled Bile Acid Receptor 1 (2)

HBV (1)

HCV (2)

HDAC (1)

Histamine Receptor (1)

Histone Methyltransferase (1)

HIV (13)

Influenza Virus (1)

Isotope-Labeled Compounds (6)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

MMP (1)

PAI-1 (1)

Parasite (17)

PKC (1)

Ser/Thr Protease (3)

Toll-like Receptor (TLR) (18)

VEGFR (2)

Virus Protease (7)

By Research Areas:

Cancer (24)

Cardiovascular Disease (2)

Infection (75)

Inflammation/Immunology (9)

Metabolic Disease (10)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163713

SARS-CoV-2-IN-89	SARS-CoV	Infection
SARS-CoV-2-IN-89 (Compound 2) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-162604

SARS-CoV-2-IN-90	SARS-CoV	Infection
SARS-CoV-2-IN-90 (compound 3i) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .

HY-157305

Jun11165	SARS-CoV	Infection
Jun11165 is a SARS-CoV-2 PL ^pro inhibitor (IC₅₀ ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC₅₀ value of ≤ 6 μM. Jun11165 can be used in the research of viral infections .

HY-146381

SARS-CoV-2-IN-20	SARS-CoV	Infection
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-146379

SARS-CoV-2-IN-19	SARS-CoV	Infection
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .

HY-168916

Jun13296	SARS-CoV Virus Protease
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13 µM, K_i = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .

HY-168441

NCGC00537446	SARS-CoV	Infection
NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .

HY-163912

JZD-07	SARS-CoV	Infection
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of *SARS-CoV-2* infection .

HY-161261

SARS-CoV-2-IN-81	AAK1 SARS-CoV	Infection
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC₅₀ value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against *SARS-CoV-2. SARS-CoV-2-IN-81* attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection .

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-169092

PF-07957472	SARS-CoV Virus Protease	Infection
PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC₅₀ = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-170767

SARS-CoV-2-IN-109	SARS-CoV	Infection
SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting *SARS-CoV* with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC₅₀=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC₅₀=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 M ^pro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of *SARS-CoV-2* and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-104077A

Remdesivir maleate GS-5734 maleate	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir maleate, a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir maleate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-161844

Virapinib	SARS-CoV	Infection
Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by *SARS-CoV-2, as well as by additional viruses, such as mpox virus* and TBEV .

HY-19727A

FOY 251 2 Publications Verification	Ser/Thr Protease SARS-CoV	Metabolic Disease
FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-104077

Remdesivir 170+ Cited Publications GS-5734	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of *SARS-CoV-2. It effectively blocks the infection* and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-19727

FOY 251 free base	Ser/Thr Protease SARS-CoV	Infection Metabolic Disease
FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor . FOY 25 free base inhibits SARS-CoV-2 infection in cells assay .

HY-136597

Remdesivir O-desphosphate acetonide impurity 2 Publications Verification	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-171160

WYFA-15	SARS-CoV	Infection
WYFA-15 is a sphingomyelin synthase 1 (SMS1) inhibitor that protects mice against lethal SFTSV infection and reduce *SARS-CoV-2* replication and pathogenesis. WYFA-15 can be utilized in anti-virus research .

HY-144798

FWM-5	SARS-CoV	Infection
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .

HY-170504

ZHAWOC25153	SARS-CoV Virus Protease	Infection
ZHAWOC25153 (Compound 17o) is a SARS-CoV-2 papain-like cysteine protease (PLpro) inhibitor, with an IC₅₀ of 7 μM. ZHAWOC25153 exhibits antiviral activity and can be used in research within the field of anti-infection .

HY-149050

Viral polymerase-IN-1 hydrochloride	Influenza Virus SARS-CoV	Infection
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC₉₀ values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against *SARS-CoV-2* infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .

HY-B1370A

(S)-Hydroxychloroquine (S)-HCQ	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection
(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine . Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro .

HY-104077R

Remdesivir (Standard)	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir (Standard) is the analytical standard of Remdesivir. This product is intended for research and analytical applications. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC₅₀s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for *SARS-CoV-2* and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-B1370B

(R)-Hydroxychloroquine (R)-HCQ	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection
(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-B1370

Hydroxychloroquine sulfate 60+ Cited Publications HCQ sulfate	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits *SARS-CoV-2* infection in vitro .

HY-131263

Hydroxychloroquine Impurity F	Drug Metabolite	Others
Hydroxychloroquine Impurity F is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits *SARS-CoV-2* infection in vitro .

HY-N10109A

Gallinamide A TFA	SARS-CoV Parasite Cathepsin	Infection
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-131262

Hydroxychloroquine Impurity E 4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol	SARS-CoV Toll-like Receptor (TLR)	Others
Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits *SARS-CoV-2* infection in vitro .

HY-B0372A

Bromhexine hydrochloride 3 Publications Verification	SARS-CoV Autophagy HIV	Metabolic Disease
Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC₅₀ of 0.75 μM. Bromhexine hydrochloride can prevent and manage *SARS-CoV-2* infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions .

HY-136606

SARS-CoV MPro-IN-1	SARS-CoV	Infection
SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC₅₀ of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC₅₀ of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .

HY-137958A

Bemnifosbuvir 1 Publications Verification AT-511	HCV SARS-CoV	Infection
Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₉₀=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity .

HY-154990

RdRP-IN-7	SARS-CoV	Infection
RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC₅₀ of 8.2 μM, an IC₉₀ of 14.1 μM and an CC₉₀ of 79.1 μM. RdRP-IN-7 can be used for antiviral research .

HY-169977

CKP-25	SARS-CoV	Infection
CKP-25 is an inhibitor for the interaction between Spike RBD-ACE2, that prevents the virus from entering the host cell, thereby reducing the replication and virus infection. CKP-25 inhibits *SARS-CoV-2* with IC₅₀ of 3.5 μM in Vero E6 cell .

HY-W031727S1

Hydroxychloroquine-d5	Autophagy SARS-CoV Toll-like Receptor (TLR) Parasite	Cancer
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].

HY-17589

Chloroquine phosphate Maximum Cited Publications 770 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-W031727S

Hydroxychloroquine-d4-1 sulfate	Isotope-Labeled Compounds Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-145592

Ruzotolimod RO7020531; RG7854	Toll-like Receptor (TLR) SARS-CoV HBV	Infection
Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or *SARS-CoV-2* .

HY-17589B

Chloroquine dihydrochloride Maximum Cited Publications 770 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine dihydrochloride is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Bacterial Antibiotic	Infection
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Antibiotic HIV SARS-CoV	Infection
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-17589A

Chloroquine Maximum Cited Publications 770 Publications Verification	Parasite Autophagy SARS-CoV Toll-like Receptor (TLR) HIV Antibiotic	Infection Inflammation/Immunology Cancer
Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-162484

GZNL-P36	SARS-CoV Virus Protease	Infection
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^pro), with an IC₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C_max of 549 ng/mL, a half-life T_1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .

Cat. No.	Product Name	Target	Research Area

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

Cat. No.	Product Name	Target	Research Area

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10109A

Gallinamide A TFA	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Parasite Cathepsin
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Infection Structural Classification Microorganisms Source classification Polyphenols Disease Research Fields	Bacterial Antibiotic
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-126419

Kobophenol A	Infection Classification of Application Fields Source classification Cyperaceae Phenols Polyphenols Plants Disease Research Fields Carex kobomugi Ohwi	SARS-CoV PKC
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC₅₀ of 1.81 μM and inhibits *SARS-CoV-2* viral infection in cells with an EC₅₀ of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC₅₀ of 52 µM .

HY-110066

(Z)-Guggulsterone 5 Publications Verification	Structural Classification Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and *SARS-CoV-2* infection .

HY-B1513

α-Cyclodextrin 2 Publications Verification	Structural Classification Zea mays L. Polysaccharides Classification of Application Fields Gramineae Source classification Other Diseases Plants Disease Research Fields Saccharides	Microtubule/Tubulin SARS-CoV
α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against *SARS-CoV-2* infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 16 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing *SARS-CoV-2* infection. Orally active .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Structural Classification Source classification Phenols Polyphenols Endogenous metabolite	Antibiotic HIV SARS-CoV
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-N14351

Ferrocin A	Structural Classification Natural Products Microorganisms Source classification	SARS-CoV Bacterial Antibiotic
Ferrocin A is a lipopeptide compound that targets the *SARS-CoV-2* RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections .

HY-110066R

(Z)-Guggulsterone (Standard)	Structural Classification Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Steroids	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-13771R

Ursodeoxycholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Source classification Disease markers Endogenous metabolite Steroids	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

Cat. No.	Product Name	Chemical Structure

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine[1]. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

HY-104077S1

Remdesivir-d4
Remdesivir-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

HY-104077S2

Remdesivir impurity 9-d4
Remdesivir impurity 9-d₄ is deuterium labeled Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro[1][2].

Cat. No.	Product Name		Classification